Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis

OBJECTIVES: In year 2016, Danish national guidelines included a mandatory switch of patients with inflammatory rheumatic diseases treated with originator etanercept (ETA) to biosimilar SB4 in routine care. We aimed to explore if switching lead to increased healthcare utilisation and costs. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Glintborg, Bente, Ibsen, Rikke, Bilbo, Rebecca Elisabeth Qwist, Lund Hetland, Merete, Kjellberg, Jakob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691512/
https://www.ncbi.nlm.nih.gov/pubmed/31452931
http://dx.doi.org/10.1136/rmdopen-2019-001016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691512/
https://www.ncbi.nlm.nih.gov/pubmed/31452931
http://dx.doi.org/10.1136/rmdopen-2019-001016

Ejemplares similares